PLCG2 and B-cell chronic lymphocytic leukemia: Similar to PLCγ2, the degree of both p-AKT and p-ERK inhibition is inversely correlated with the IC50 of cerdulatinib in 43 CLL samples suggesting the anti-tumor effect of cerdulatinib relates to its inhibition of distal signal transducers AKT and ERK (Figure 6B bottom).